Halozyme To Host Second Quarter 2021 Financial Results Webcast and Conference CallPRNewsWire • 07/27/21
Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent RelapsePRNewsWire • 07/12/21
Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple MyelomaPRNewsWire • 06/22/21
GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme DealBenzinga • 06/22/21
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIVBusiness Wire • 06/22/21
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIVPRNewsWire • 06/22/21
Why Is Halozyme Therapeutics (HALO) Down 7.5% Since Last Earnings Report?Zacks Investment Research • 06/09/21
Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPRNewsWire • 06/01/21
Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®PRNewsWire • 05/21/21
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/11/21
Halozyme Therapeutics (HALO) Tops Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/10/21
Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference CallPRNewsWire • 04/20/21
Halozyme Therapeutics (HALO) Down 19.3% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/25/21